Anixa Biosciences Inc. has announced the initiation of dosing in the fourth cohort of its ongoing Phase 1 clinical trial for a novel CAR-T therapy targeting recurrent ovarian cancer. This cohort will receive a dose of three million CAR-positive cells per kilogram, which is thirty times higher than the initial dose administered in the first cohort. The trial, conducted in partnership with Moffitt Cancer Center, aims to evaluate the safety and therapeutic potential of this treatment. No dose-limiting toxicities were observed in the previous cohort, allowing the progression to this higher dose. The study is currently focused on safety and determining the maximum tolerated dose, with promising early signs of potential efficacy. Results from this study are yet to be presented.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。